Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Adverse event reporting for botulinum toxin type A.

R Sonia Batra, Jeffrey S Dover, Kenneth A Arndt

Journal of the American Academy of Dermatology

|November 29, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of a Core Outcome Domain Set for Facial Aging.

JAMA dermatology·2026

Same author

Lasers and Acquired Melanocytic Nevi: A Systematic Review.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2026

Same author

Restorative cosmetic dermatology: Utilizing cosmetic procedures to correct appearance and function in patients with medical dermatologic conditions - Part II. Condition-specific applications.

Journal of the American Academy of Dermatology·2026

Same author

Restorative cosmetic dermatology: Utilizing cosmetic procedures to correct appearance and function in patients with medical dermatologic conditions - Part I. Principles of restorative cosmetic dermatology & core techniques.

Journal of the American Academy of Dermatology·2026

Same author

Consensus Panel Recommendations for Optimizing Use of a Contact-Cooled 1726 nm Laser for the Treatment of Acne.

Journal of cosmetic dermatology·2026

Same author

Comparing ChatGPT Informed Consent Documentations for Energy-Based Devices.

Lasers in surgery and medicine·2025

Adverse events from botulinum toxin type A (BTX-A) use were reviewed, finding no deaths from cosmetic applications. Therapeutic BTX-A use showed a higher rate of serious adverse events compared to cosmetic use.

Area of Science:

Dermatology
Pharmacovigilance
Medical Aesthetics

Background:

A review analyzed Food and Drug Administration (FDA) adverse event reports for botulinum toxin type A (BTX-A) from 1989-2003.
The majority of reported events pertained to therapeutic applications rather than cosmetic use.
Postmarketing surveillance data requires careful interpretation regarding causality and context.

Discussion:

Serious adverse events were significantly more frequent in therapeutic BTX-A use (33-fold higher) compared to cosmetic use.
No fatalities were reported in association with cosmetic BTX-A applications.
Over one-third of reported events involved off-label BTX-A usage, common in dermatological practice.

Key Insights:

The analysis indicates a favorable safety profile for cosmetic applications of BTX-A.

Related Experiment Videos

No significant difference in adverse event rates was observed between on-label and off-label BTX-A use.

Spontaneous reporting systems do not establish causal links between BTX-A and adverse events.

Outlook:

Misinterpretation of spontaneous adverse event data could lead to inaccurate conclusions about BTX-A safety.
Continued vigilance in pharmacovigilance is essential for both therapeutic and cosmetic uses of BTX-A.
The study underscores the generally safe and effective nature of BTX-A for cosmetic purposes when used appropriately.